Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
Views & Analysis PPRS and devolution: over £60m to Greater Manchester? Does the local NHS in England get its fair share of PPRS money?
Views & Analysis Meeting the challenges of rare disease treatment adherence HCPs, pharma and patients can pool their experience to develop effective, tailored support.
Views & Analysis Fighting diminishing HCP access Predictive sales analytics can help pharma reps make limited time with healthcare professionals count.
Views & Analysis Saving the jewel in the crown of ‘UKplc’: Brexit's impact on... Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
Partner Content Partner Content The new CDF - Navigating Cancer Drug Access in England On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
